A Randomized, Multicenter Study To Evaluate The Efficacy And Safety Of Apatinib Versus Docetaxel In Patients With Previously Treated Locally Advanced Or Metastatic Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Latest Information Update: 03 Nov 2017
At a glance
- Drugs Rivoceranib (Primary) ; Docetaxel
- Indications Gastric cancer
- Focus Therapeutic Use
- 17 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 10 Apr 2015 New trial record